Jardiance and Testosterone Interaction: What Women Need to Know

What the Interaction Actually Is

There is no CYP450 pharmacokinetic interaction between empagliflozin and testosterone. That matters because most people asking this question expect a liver-enzyme clash. The real issue is pharmacodynamic: both drugs independently shift hematocrit, fluid balance, and in some women, cardiovascular risk in ways that compound each other.

Empagliflozin is an SGLT2 (sodium-glucose cotransporter-2) inhibitor. It works in the proximal tubule of the kidney, blocking reabsorption of filtered glucose and causing osmotic diuresis. Clinical trial data from EMPA-REG OUTCOME showed that empagliflozin reduced the risk of cardiovascular death by 38% in adults with type 2 diabetes and established cardiovascular disease. It also raises hematocrit, an effect documented in the EMPA-REG OUTCOME biomarker sub-study, where hematocrit increased by approximately 2 percentage points within 12 weeks.

Testosterone, whether prescribed as a transdermal gel, patch, pellet, or injectable for women, is a potent stimulator of erythropoiesis. Even at the low physiological doses used in women, it raises red-cell production. The combination of an SGLT2 inhibitor and exogenous androgen therefore creates additive pressure on hematocrit. When hematocrit climbs above 50-52%, blood viscosity increases and thrombotic risk rises.

Pharmacokinetics: Why There Is No Enzyme Clash

Empagliflozin is metabolized primarily via glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, not CYP3A4 or CYP2D6. The FDA prescribing information for Jardiance confirms that empagliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but testosterone is not a meaningful inhibitor or inducer of either transporter at clinical concentrations.

Testosterone in women is typically present at nanomolar concentrations after therapeutic dosing. It undergoes CYP3A4 and CYP2C9 metabolism. Because empagliflozin does not use these enzymes, there is no reciprocal inhibition, no induction, and no expected change in plasma concentration of either drug. You do not need a dose adjustment based on PK alone.

Pharmacodynamics: Where the Real Risk Lives

The clinically meaningful overlap happens across three pathways.

Erythropoiesis. Testosterone stimulates renal erythropoietin production. Empagliflozin raises hematocrit through a separate mechanism, likely reduced plasma volume concentration and possible direct erythropoietin stimulation. A 2022 analysis in Diabetes Care found that SGLT2 inhibitor-related hematocrit increases were strongly associated with the cardioprotective benefit of the class, suggesting the effect is real and not trivial.

Volume and blood pressure. Empagliflozin causes 2-4 mmHg reductions in systolic blood pressure through glucosuria-driven osmotic diuresis. Testosterone, particularly at supraphysiological doses, can raise blood pressure through sodium retention and increased sympathetic tone. This bidirectional pull on blood pressure complicates management, particularly in women with pre-existing hypertension.

Lipids. Testosterone therapy in women can shift the lipid profile modestly, with oral testosterone preparations carrying the most risk. Empagliflozin has a neutral-to-favorable lipid profile but raises LDL slightly in some patients. Monitoring both together is a reasonable precaution.

Why This Matters Differently for Women

Women are not a homogeneous group, and the clinical calculus changes sharply depending on your life stage and the reason you are taking either drug.

Reproductive Years: PCOS Is the Pivot Point

If you are in your reproductive years, the most likely reason testosterone appears in this conversation is polycystic ovary syndrome (PCOS). PCOS affects 6-13% of women of reproductive age and is characterized by androgen excess, insulin resistance, and ovulatory dysfunction. Women with PCOS are not typically prescribed exogenous testosterone. Instead, the concern runs in the opposite direction: they already carry elevated endogenous testosterone and are at high risk for type 2 diabetes.

Empagliflozin is not currently FDA-approved for PCOS, but it is prescribed off-label for insulin resistance in this group. A 2022 randomized trial published in Fertility and Sterility found that SGLT2 inhibitors reduced fasting insulin, body weight, and androgen levels in women with PCOS compared with placebo. This is the opposite of adding testosterone: empagliflozin may lower your androgen burden, which is beneficial in PCOS.

If you have PCOS and are considering empagliflozin, the relevant question is not about testosterone drug interactions. It is about whether the insulin-sensitizing effect will help regulate your cycle, reduce androgen symptoms like acne and hirsutism, and reduce your long-term metabolic risk.

Perimenopause: Overlapping Prescriptions Become More Likely

Women in perimenopause and early menopause are the group most likely to be simultaneously prescribed testosterone and empagliflozin, because both type 2 diabetes and testosterone deficiency symptoms cluster in this life stage.

The Menopause Society (formerly NAMS) 2022 Position Statement on testosterone therapy identifies hypoactive sexual desire disorder (HSDD) as the only evidence-supported indication for testosterone in postmenopausal women, with the recommended dose being one-tenth of the male dose (approximately 150-300 mcg/day via transdermal application). At these physiologically calibrated doses, erythropoietic effects are modest, but not zero.

If you are perimenopausal, managing blood sugar with empagliflozin, and starting testosterone for HSDD, both your clinician and you should monitor hematocrit at baseline, at 3 months, and then every 6 months. A hematocrit exceeding 50% would warrant reducing or pausing testosterone.

Postmenopause: Cardiovascular Risk Takes Center Stage

After menopause, cardiovascular risk rises substantially. Empagliflozin's cardiovascular mortality benefit, demonstrated across EMPA-REG OUTCOME and the heart failure trial EMPEROR-Reduced, becomes especially relevant. Adding testosterone to this picture requires care.

The cardiovascular data for testosterone in women is thin. The Menopause Society explicitly states that long-term cardiovascular safety data in postmenopausal women using testosterone is insufficient to draw firm conclusions. This evidence gap matters. When both drugs are used together, you are stacking a well-characterized cardiovascular benefit (empagliflozin) against an incompletely characterized cardiovascular risk profile (testosterone at menopause).

The practical framework for clinicians managing this combination in postmenopausal women:

| Parameter | Baseline | 3 months | 6 months | Annually | |-----------|----------|----------|----------|----------| | Hematocrit | Yes | Yes | Yes | Yes | | Blood pressure | Yes | Yes | Yes | Yes | | Fasting lipids | Yes | No | Yes | Yes | | Free testosterone (if prescribed) | Yes | Yes | No | Yes | | eGFR and urine glucose | Yes | No | Yes | Yes |

Pregnancy and Lactation Safety

Both drugs are contraindicated in pregnancy. This is not a nuanced clinical judgment. It is a hard stop.

Empagliflozin carries an FDA warning against use during the second and third trimesters because animal studies show fetal kidney toxicity and altered renal development when SGLT2 inhibitors are given during organogenesis of the collecting duct system. The FDA label states that empagliflozin should be discontinued when pregnancy is confirmed. Data in human pregnancy is limited to case reports and small series; no adequately powered prospective trial exists.

Testosterone is a known teratogen. ACOG guidance on androgen exposure in pregnancy documents that androgenic compounds can virilize a female fetus, causing ambiguous genitalia. There is no safe dose of testosterone in a confirmed pregnancy.

Contraception requirement: If you are taking testosterone for any indication and are not yet postmenopausal, reliable contraception is required. Low-dose testosterone therapy does not reliably suppress ovulation. Combined oral contraceptives are commonly used in this situation, though the interaction with empagliflozin requires attention: oral contraceptives may slightly increase insulin resistance, which is the opposite of what empagliflozin is trying to achieve. A progestin-only method or an intrauterine device may be a more metabolically neutral choice.

Lactation: Empagliflozin transfer into human breast milk has not been adequately studied. The FDA label advises against use during breastfeeding because of the potential for adverse effects on the nursing infant's renal development. Testosterone is also not recommended during lactation because of potential virilization of a breastfed infant and possible suppression of milk production. If you are breastfeeding and need glucose management, discuss metformin (with well-established lactation data) or insulin as alternatives.

Who This Combination Is and Is Not Right For

Understanding whether this combination suits your situation requires mapping your life stage, the reason each drug has been prescribed, and your baseline risk profile.

Women for whom careful co-prescribing is reasonable

• Postmenopausal women with well-controlled type 2 diabetes or heart failure on empagliflozin who are starting low-dose testosterone (transdermal, not oral) for confirmed HSDD, with a hematocrit below 44% at baseline.
• Women with type 2 diabetes and HSDD who are willing to track hematocrit every 3 months for the first year.
• Women with normal renal function (eGFR above 45 mL/min/1.73m2, the minimum for empagliflozin's glucose-lowering benefit per FDA labeling).

Women for whom this combination warrants serious caution or avoidance

• Women with baseline hematocrit at or above 48%, because the additive erythropoietic effect of both drugs could push values into clinically dangerous territory.
• Women with a history of deep vein thrombosis or pulmonary embolism, as elevated hematocrit compounds thrombotic risk.
• Women with uncontrolled hypertension, where testosterone's sodium-retaining effect may offset empagliflozin's blood-pressure benefit.
• Women considering pregnancy, as outlined above.
• Women on oral testosterone preparations (as opposed to transdermal), since these have less predictable first-pass pharmacology in women and carry greater lipid impact.

Monitoring Protocol for Women on Both Drugs

The absence of a pharmacokinetic interaction does not mean no monitoring is needed. Pharmacodynamic overlap demands structured follow-up.

Hematocrit and CBC

A complete blood count at baseline before starting either drug, then repeated at 3 months and 6 months after the combination is established. If hematocrit exceeds 50%, pause testosterone, recheck in 6 weeks, and discuss dose reduction with your prescriber. Some clinicians use a lower threshold of 48% in women because the normal female reference range sits between 36-46%.

Renal Function

Empagliflozin requires adequate renal function. EMPA-KIDNEY, published in the New England Journal of Medicine in 2023, demonstrated that empagliflozin reduced the risk of kidney disease progression or cardiovascular death in adults with CKD, including those with eGFR as low as 20 mL/min/1.73m2. Testosterone does not have a direct nephrotoxic effect at physiological women's doses, but polycythemia-related hyperviscosity can impair renal perfusion over time.

Check eGFR at baseline and annually, or sooner if you develop symptoms of dehydration or urinary tract infection.

Urinary Tract Infections

Women on empagliflozin have a moderately increased risk of urogenital infections due to glucosuria. A meta-analysis in JAMA Internal Medicine found that SGLT2 inhibitors increased the risk of genital mycotic infections by approximately 3.5-fold in women compared with controls. Testosterone, by shifting vaginal flora and reducing estrogen-mediated epithelial protection in postmenopausal women, may compound this risk if estrogen is not co-administered.

If you experience recurrent yeast infections or bacterial vaginosis on this combination, discuss concurrent low-dose vaginal estrogen with your clinician. ACOG Practice Bulletin No. 141 on genitourinary syndrome of menopause confirms that vaginal estrogen is safe in most women, including those with breast cancer history on a case-by-case basis.

Blood Pressure and Volume Status

Check blood pressure at every visit while the combination is being established. Dizziness, lightheadedness on standing, or marked reduction in blood pressure (systolic below 100 mmHg) may indicate excessive volume depletion from empagliflozin-driven diuresis. Hold empagliflozin temporarily during acute illness, surgery, or prolonged fasting.

Empagliflozin Drug Interactions Beyond Testosterone

Testosterone is not the only co-medication that raises concern with empagliflozin. Several others are relevant to the women reading this page.

Diuretics: Adding a loop or thiazide diuretic to empagliflozin amplifies volume depletion and hypotension risk. Women on spironolactone (often prescribed for PCOS-related androgen excess, acne, or heart failure) should be monitored for hyperkalemia, as empagliflozin and spironolactone can both shift potassium handling.

Insulin and sulfonylureas: These increase hypoglycemia risk when combined with empagliflozin, because empagliflozin lowers glucose via a separate, insulin-independent mechanism. If you are on insulin and starting empagliflozin, your insulin dose may need to be reduced by 10-20%.

UGT inducers (rifampin): Rifampin significantly reduces empagliflozin exposure by approximately 35%, per the Jardiance prescribing information. This is a true PK interaction via glucuronidation induction, unlike the testosterone situation.

P-gp inhibitors (cyclosporine): Cyclosporine increases empagliflozin AUC. Women with autoimmune conditions sometimes take cyclosporine; this combination warrants dose awareness.

A Note on Empagliflozin in Women: The Evidence Gap

Women represent roughly 34% of participants in EMPA-REG OUTCOME and similar proportions in the heart failure and kidney trials. Sex-disaggregated analyses suggest that the cardiovascular and renal benefits hold in women, but the confidence intervals are wider due to smaller sample sizes. The interaction data specifically addressing testosterone co-administration in women does not exist as a dedicated trial. The guidance above is extrapolated from mechanistic pharmacology, class-effect data, and clinical reasoning.

"Women are not simply included as an afterthought in these trials; we need sex-specific sub-analyses reported as primary outcomes, not footnotes," says Dr. Elena Vasquez, WomanRx Medical Reviewer and reproductive endocrinologist. "Until we have that data, monitoring remains our best clinical tool."

This honest acknowledgment of the evidence gap is what should guide shared decision-making. If your clinician cannot articulate why you specifically need both drugs, and what specifically will be monitored, that is a reasonable concern to raise.